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Introduction: Noninvasive ventilation (NIV) improves survival among patients with 
hypercapnic respiratory failure in hospital, but evidence for its use in domiciliary settings is 
limited. A patient’s underlying risk of having an exacerbation may affect any potential benefit 
that can be gained from domiciliary NIV. This is the first comprehensive systematic review 
to stratify patients based on a proxy for exacerbation risk: patients in a stable state and those 
immediately post-exacerbation hospitalization.
Methods: A systematic review of nonrandomized and randomized controlled trials (RCTs) was 
undertaken in order to compare the relative effectiveness of different types of domiciliary NIV 
and usual care on hospital admissions, mortality, and health-related quality of life. Standard 
systematic review methods were used for identifying studies (until September 2014), quality 
appraisal, and synthesis. Data were presented in forest plots and pooled where appropriate using 
random-effects meta-analysis.
Results: Thirty-one studies were included. For stable patients, there was no evidence of a 
survival benefit from NIV (relative risk [RR] 0.88 [0.55, 1.43], I2=60.4%, n=7 RCTs), but 
there was a possible trend toward fewer hospitalizations (weighted mean difference -0.46 
[-1.02, 0.09], I2=59.2%, n=5 RCTs) and improved health-related quality of life. For posthospital 
patients, survival benefit could not be demonstrated within the three RCTs (RR 0.89 [0.53, 1.49], 
I2=25.1%), although there was evidence of benefit from four non-RCTs (RR 0.45 [0.32, 
0.65], I2=0%). Effects on hospitalizations were inconsistent. Post hoc analyses suggested that 
NIV-related improvements in hypercapnia were associated with reduced hospital admissions 
across both populations. Little data were available comparing different types of NIV.
Conclusion: The effectiveness of domiciliary NIV remains uncertain; however, some patients 
may benefit. Further research is required to identify these patients and to explore the relevance 
of improvements in hypercapnia in influencing clinical outcomes. Optimum time points for 
commencing domiciliary NIV and equipment settings need to be established.
Keywords: noninvasive ventilation, domiciliary, COPD, hospitalization, systematic review, 
meta-analysis
Introduction
COPD is a chronic progressive lung disease, characterized by nonreversible airflow 
obstruction and intermittent exacerbations.1 Treatment for COPD is based on phar-
macotherapy, pulmonary rehabilitation, and in some cases, long-term oxygen therapy. 
Exacerbations are a key cause of increased morbidity, mortality, and poor health status, 
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and place a considerable burden on the health care system.2 
Approximately 15% of COPD patients per year have exac-
erbations necessitating hospital admission;3,4 between 10% 
and 25% of patients admitted with hypercapnic respiratory 
failure due to COPD die in hospital.5 Reduced exacerbation 
frequency is therefore an important therapeutic target.
Noninvasive ventilation (NIV) is a method of providing 
ventilatory support via a mask and is effective in improv-
ing survival among patients with acute or acute-on-chronic 
hypercapnic respiratory failure in hospital.6,7 Evidence for 
domiciliary use of NIV in non-acute COPD patients is 
more limited despite a number of systematic reviews.8–11 
As patients immediately posthospitalization are at greater 
risk of recurrence of exacerbation than those more stable,12 
this difference could influence the effectiveness of NIV 
in preventing or reducing the impact of these events. This 
is the first systematic review to stratify data by these two 
patient groups, and it is the most comprehensive review to 
date, including evidence from randomized controlled trials 
(RCTs), non-RCTs, and RCTs comparing different NIV set-
tings, and considering mortality, hospitalizations, and quality 
of life (QoL) as outcomes. Finally, this is the first systematic 
review to attempt an analysis, albeit exploratory, of the rela-
tionship between hypercapnia and clinical outcomes.
Methods
A protocol detailing the methodology was registered with 
PROSPERO (CRD42012003286).13,14 A summary of the 
methods is presented here. Search strategies incorporated a 
combination of text words and index terms relating to NIV 
and COPD. Bibliographic databases (MEDLINE, MED-
LINE In-Process, Embase, Cochrane CENTRAL, CINAHL, 
and Science Citation Index Expanded (ISI)), the British 
Library’s ZETOC and ISI Conference Proceedings Citation 
Index, and clinical trial registers were searched from 1980 
until September 2014. No study design or language restric-
tions were imposed. Citation checking of included studies 
was undertaken, and experts in the field were consulted to 
identify further studies. The search strategy for MEDLINE 
is shown in the Supplementary material.
Studies were eligible for inclusion if they met the criteria 
shown in Table 1.
Primary outcomes of interest were mortality, hospi-
talizations, exacerbations, and QoL. Secondary outcomes 
included lung function and blood gases. Study selection 
was performed by two reviewers independently. Disagree-
ments were resolved through discussion and/or referral to a 
third reviewer.
Risk of bias was assessed based on the Cochrane col-
laboration risk-of-bias tool (for RCTs and nonrandomized 
controlled studies), and additional criteria were considered 
for crossover trials (ie, whether there was a carry-over 
effect, whether only first-period data were available, whether 
analysis was appropriate to crossover trials, and comparability 
of results with those from parallel-group trials).15
Data extraction was performed by one reviewer using a 
standardized, piloted data extraction form, and numerical data 
were checked by a second reviewer. Study selection and data 
extraction of non-English language papers was performed by 
native speakers of the respective languages with guidance 
from the reviewers.
Studies were grouped according to average proximity 
of patients to their most recent exacerbation that required 
hospitalization. If patients had not been hospitalized within 
4 weeks to 3 months at commencement of the study or 
were described as “stable”, they were classed as the stable 
population. Where there was clear evidence that treatment 
with NIV in a study commenced after an episode of hos-
pitalization (due to an exacerbation), these patients were 
classed as the posthospital population, with the assumption 
that on average, this population were at greater risk of a 
subsequent exacerbation.
Separate analyses were performed for each study design 
(RCT, controlled studies) and primary outcome (survival 
and hospitalizations). Where there was clinical and meth-
odological homogeneity between studies reporting the same 
outcome and using the same outcome statistic (reported or 
calculable), random effects meta-analysis was undertaken in 
STATA (Stata Statistical Software: Release 10; StataCorp 
LP, College Station, TX, USA). Results for other primary 
outcomes were reported narratively (exacerbations and 
QoL). Secondary outcome data (forced expiratory volume 
in 1 second, forced vital capacity, partial pressure of carbon 
dioxide [PaCO
2
], partial pressure of oxygen, 6-minute 
Table 1 study inclusion criteria
Study design Patients Intervention Comparator
rCTs (parallel or crossover) adult COPD  
patients
any form of  
domiciliary nIV
Usual care or another 
form of nIVnonrandomized controlled studies
systematic reviews (for identifying further primary studies)
Abbreviations: rCTs, randomized controlled trials; nIV, noninvasive ventilation.
International Journal of COPD 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2271
systematic review of domiciliary noninvasive ventilation in COPD
walk distance) were not pooled due to between-study het-
erogeneity but are presented in forest plots in order to show 
the overall direction of effect and uncertainty.
Exploratory post hoc analyses of study-level data were 
performed to determine if baseline hypercapnia could predict 
response to NIV, or whether change in hypercapnia correlated 
with any effect of NIV on mortality and hospitalizations.
Guidelines of Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses were adhered to.16
Results
Main study characteristics
Screening of the 7,405 records identified by the searches 
yielded 21 RCTs (18 NIV vs usual care; three NIV vs another 
form of NIV) and ten nonrandomized controlled studies (five 
prospective, five retrospective; Figure 1). Table 2 shows the 
main characteristics of these studies.
All patients had Global Initiative for Chronic Obstructive 
Lung Disease stage III and/or IV COPD, or were described as 
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LQJ
(OLJ
LELOL
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,QFO
XGH
G
5HFRUGVLGHQWLILHGWKURXJKGDWDEDVHVHDUFKLQJDQGRWKHUVRXUFHVDIWHUDXWRPDWLFUHPRYDORIGXSOLFDWHVQ 
5HFRUGVVFUHHQHGQ 
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1,9YV1,9Q VWXGLHV
3URVSHFWLYHQ VWXGLHV
5HWURVSHFWLYHQ VWXGLHV
Figure 1 PRISMA flow diagram (study selection process).
Abbreviations: PrIsMa, Preferred reporting Items for systematic reviews and Meta-analyses; rCTs, randomized controlled trials; nIV, noninvasive ventilation.
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“severe” (where reported). Eighteen studies provided details 
on assessing patients for obstructive sleep apnea, to rule out 
overlap syndrome. Twenty studies were on stable popula-
tions and nine on posthospital populations, and there were 
no details for two. For posthospital populations, there was 
clear evidence in all study reports that NIV treatment com-
menced after hospitalization due to an exacerbation. For both 
populations, there was usually no information on the length 
of time before NIV was initiated, or previous exacerbation 
history. Varying proportions of patients were on long-term 
oxygen therapy. Most studies included hypercapnic patients, 
though the cut-off for classification varied. Two RCTs17,18 
included normocapnic patients, while one RCT19 stated that 
the number of hypercapnic patients included was small.
NIV settings, therapeutic/tolerability targets (pressure, 
volume, or blood gases), and reporting of these varied across 
studies. There was some variability in usual care, with three 
studies considered to have more intensive approaches to 
usual care: a 12-week multidisciplinary rehabilitation pro-
gram, followed by a long-term home-based rehabilitation 
program,20,21 a pulmonary rehabilitation program for part of 
the RCT,18 and a “home supervision program”.22
There was a lack of reporting of some details relevant 
to study quality, particularly regarding loss to follow-up, 
handling of missing data, and blinding of outcome asses-
sors. Only three RCTs included a “sham NIV” arm, lack 
of which may have led to performance bias and/or bias in 
patient-reported QoL. By definition, the nonrandomized 
studies were more prone to bias; some retrospective studies 
had clear evidence of baseline imbalances between NIV and 
comparator groups, with the consequence of this on study 
findings unknown.
Length of follow-up varied between 3 and 24 months 
(RCTs) and between 12 months and 10 years (controlled 
studies). The longest follow-up periods (4–10 years) were 
in the retrospective controlled studies.
Main findings
nIV compared with usual care only: stable population
Data from seven RCTs19,21,23–27 (pooled relative risk [RR] 
0.88 [0.55, 1.43], I2=60.4%) and four controlled studies22,28–30 
(pooled RR 1.19 [0.65, 2.18], I2=0%) suggested no significant 
difference between domiciliary NIV and usual care alone in 
terms of survival up to 24 months (Figure 2). Excluding the 
RCT by Casanova et al,19 which included only few patients 
with hypercapnia, had little effect, changing the pooled RR 
to 0.85 (0.46, 1.58). Data from five RCTs21,23–25,27 and three 
controlled studies22,28,29 (Figure 3) suggested a trend toward 
fewer hospital admissions/days in hospital with NIV, albeit 
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not statistically significant. Evidence on exacerbations not 
leading to hospitalization based on four RCTs17,19,21,24 and 
one controlled study29 showed no significant effect of NIV 
(Supplementary material). For QoL, there appeared to be 
a trend favoring NIV, but a consistent benefit could not be 
demonstrated; heterogeneity in outcomes measured and time 
points hampered analyses of this measure (Supplementary 
material). There was some evidence to suggest that NIV 
improved blood gases (based on mainly unadjusted results; 
Figures 4 and 5).
nIV compared with usual care only: posthospital 
population
No survival benefit was evident from three RCTs31–33 (pooled 
RR 0.89 [0.53, 1.49], I2=25.1%), though four nonrandomized 
controlled studies,34–37 which are potentially more prone to 
bias, favored NIV (pooled RR 0.45 [0.32, 0.65], I2=0%; 
Figure 2). Findings for hospital admissions were inconsistent, 
with one RCT33 finding a statistically significant benefit of 
NIV, one31 marginally favoring NIV, and one32 marginally 
favoring usual care (without NIV) (Figure 3). QoL data were 
reported in only one posthospital RCT,32 and there were no 
differences between NIV and usual care. Limited data from 
three trials31–33 suggested a potential benefit from NIV in 
terms of reduction in PaCO
2
 (Figure 5).
study quality
None of the RCTs assessed as having a high risk of bias 
contributed data to meta-analyses; yet some of the 
nonrandomized controlled studies in the meta-analyses 
Figure 2 Mortality (relative risk).
Notes: *Calculated by authors of this report. +Controlled study with matching.
Abbreviations: RR, relative risk; CI, confidence interval; RCT, randomized controlled trial; NIV, noninvasive ventilation.
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(for both populations) did. The small number of studies 
precluded assessment of the potential for publication bias 
(eg, using funnel plots) and sensitivity analyses around 
study quality.
subgroup analysis
No further subgroup analysis (beyond study design and 
population) was possible, given the small number of trials and 
inconsistent reporting of relevant characteristics. However, 
many clinicians believe that the extent of hypercapnia or a 
change in hypercapnia status is related to the effect of NIV. 
In this context, it is worth noting that the study by Köhnlein 
et al23 had the highest hypercapnia threshold as an eligibility 
criterion (PaCO
2
 $7 kPa), and also showed a statistically 
significant survival benefit (and a nonsignificant trend toward 
fewer hospital admissions). Further, the study by Zhou et 
al,24 which along with the Köhnlein et al23 study had the 
highest mean PaCO
2
, found a statistically significant benefit 
from NIV in hospital admissions. In order to explore the 
hypercapnia level further as a potential predictor of benefit 
from NIV, data on mean PaCO
2
 levels prior to initiation of 
NIV and change in mean PaCO
2
 levels due to NIV from 
each study (where reported) were plotted against mortality 
and hospitalization data in order to determine if baseline 
PaCO
2
 levels could predict response to NIV, and whether 
the effect of NIV on PaCO
2
 levels correlates with the effect 
on clinical outcomes (Figure 6A–D). These exploratory 
analyses suggested a trend toward a correlation between 
changes in hypercapnia status and hospital admissions (based 
on eight RCTs21,23–25,27,31–33). Such a potential correlation was 
not observed for mortality (based on ten RCTs19,21,23–27,31–33). 
Baseline hypercapnia status did not appear to predict response 
to NIV for mortality (based on ten RCTs19,21,23–27,31–33); the 
data were suggestive of a possible trend toward a correlation 
between baseline hypercapnia and hospital admissions (based 
on eight RCTs21,23–25,27,31–33). Formal subgroup analysis based 
on the level of hypercapnia was however not deemed to be 
appropriate as this would have meant dichotomizing trials 
Figure 3 hospital admissions per patient per year (weighted mean difference).
Notes: *Calculated by authors of this report. #Individual mean differences (95% CI) presented for this outcome.
Abbreviations: CI, confidence interval; WMD, weighted mean difference; RCTs, randomized controlled trials; ICU, intensive care unit; NIV, noninvasive ventilation.
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based on an arbitrary CO
2
 threshold. Adherence to NIV and 
effect of NIV settings could also not be analyzed.
Different types of nIV
With regard to the effectiveness of different NIV settings, 
three small crossover trials in stable populations were identi-
fied: two38,39 comparing higher vs lower pressure NIV and 
one40 comparing different back-up rates. All were short term 
(6–8 weeks) and did not assess mortality or hospitalizations/
exacerbations. Treatment compliance was similar between 
arms in two studies,39,40 and higher in the high-pressure arm 
for the third,38 but drop-out rates were high in the pressure 
trials.38,39 The limited QoL data precluded drawing firm con-
clusions. The only statistically significant result38 was greater 
PaCO
2
 reduction with high-pressure NIV (Supplementary 
material).
Discussion
This is the first systematic review of domiciliary NIV to 
attempt to account for differing baseline risks of exacerbation 
by categorizing populations into stable and posthospital 
based on proximity to an in-patient stay for an exacerbation; 
it is also the most comprehensive review to date, including 
evidence from RCTs, nonrandomized controlled studies, 
and RCTs comparing different NIV settings, and without 
restriction to English language-only publications. Overall, the 
evidence from RCTs in a stable population could not demon-
strate benefit for mortality from domiciliary NIV compared 
to usual care alone (seven RCTs19,21,23–27 and four controlled 
studies22,28–30), although there was a trend toward fewer 
hospital admissions (five RCTs21,23–25,27 and three controlled 
studies22,28,29), and to a lesser extent, improved QoL (seven 
RCTs17,18,21,23,26,27,41 and one controlled study29), for the stable 
population. A survival benefit for the posthospital population 
could not be shown based on three RCTs,31–33 though there 
was some evidence of benefit based on four (potentially 
biased) nonrandomized controlled studies.34–37 Findings for 
hospital admissions (three RCTs31–33) were inconsistent. 
There was too little evidence to draw any conclusions on the 
potential benefits of high-pressure NIV settings.
Figure 4 PaO2 (mean difference).
Notes: *Calculated by authors of this report. aMeasurement performed regardless of oxygen use. bMeasurements both on room air or both on oxygen at the same 
flow rate.
Abbreviations: PaO2, partial pressure of oxygen; NIV, noninvasive ventilation; CI, confidence interval; NR, not reported.
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exacerbation risk and domiciliary nIV
It was hoped that subgroup analyses based on the frequency 
of exacerbations prior to NIV treatment would be pos-
sible, as frequent exacerbators (patients with two or more 
exacerbations/year) are a clinically relevant subgroup,42 with 
a generally stable exacerbation frequency on other existing 
therapies.43 However, this was hampered by lack of reporting 
of this parameter.
There is evidence, however, to support the use of recent 
hospitalization as a proxy for a higher risk of recurring exacer-
bation. Prior hospital admission is recognized to be the biggest 
driver for a further exacerbation requiring admission,12 and 
NIV use in hospital has also been recognized as a predictor 
of overall exacerbation rate.44 Furthermore, recurrent type 2 
respiratory failure, that is, respiratory failure with carbon 
dioxide retention, occurs in over 30%, and readmission at 
1 year in 60%, of those who require NIV acutely in hospital.45 
Consequently, stratification based on NIV started at recent 
hospitalization was thought to be a justifiable surrogate 
marker of exacerbation risk. In reality, there is likely to be 
much more of a continuum of risk, and it is further unknown 
what proportion of the posthospital populations considered in 
the individual studies are COPD patients at the more severe 
end of the disease spectrum.
Which patients may benefit from 
domiciliary nIV?
The results of the review show that division of data based 
on potential exacerbation risk did not indicate a difference 
between populations in terms of mortality or hospitalizations; 
in fact, there was no clear evidence for benefit for either 
population, though there was a nonsignificant trend toward 
Figure 5 PaCO2 (mean difference).
Notes: *Calculated by authors of this report. aMeasurement performed regardless of oxygen use. bMeasurements both on room air or both on oxygen at the same flow rate.
Abbreviations: PaCO2, partial pressure of carbon dioxide; NIV, noninvasive ventilation; CI, confidence interval.
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a benefit with NIV in the stable population, for hospital 
admissions. The apparent similarity in hospitalization effect 
in our chosen subgroups is perhaps surprising, given that 
those previously admitted are at higher risk of subsequent 
readmission. It is possible that the division used failed to 
capture other important differences within and between 
populations; for example, the pretreatment exacerbation rates 
were unknown. There was evidence of some heterogeneity 
between both stable and posthospital studies, with some 
studies showing a significant benefit from NIV; one RCT23 in 
a stable population showed a statistically significant benefit 
from NIV for mortality (Figure 2), and one RCT for stable24 
and two for posthospital populations31,33 showed significant 
benefit for hospital admissions (Figure 3). Two of these 
RCTs23,33 used a higher hypercapnia threshold for patient 
inclusion (PaCO
2
 .7 kPa); one RCT25 had a lower inclusion 
criterion (PaCO
2
 .6 kPa), though means were suggestive of 
higher levels. There was no detail on the inclusion threshold 
for the third RCT.24
Elements such as blood gases, prior admissions, and social 
support have been identified as drivers to clinical decision 
making regarding domiciliary NIV in COPD,46 all of which 
may impact NIV efficacy. The nonrandomized posthospital 
studies22,28–30 assessing mortality (Figure 2) suggest a ben-
eficial effect from NIV (significant pooled RR), however, 
it is possible that patient selection for NIV biased findings 
toward a positive response to NIV.
Most populations included in studies were hypercap-
nic (Table 2), although the threshold used to define this 
varied. Post hoc analyses undertaken across both stable 
and posthospital populations suggested a trend toward a 
positive correlation between changes in hypercapnia and 
hospital admissions (but not for mortality or correlation 
using pretreatment PaCO
2
 level). As these are exploratory 
analyses, the results should be interpreted cautiously; the 
analysis used aggregate – study-level – data for baseline 
hypercapnia, change in hypercapnia, and clinical outcomes, 
and a patient-level association cannot be inferred even if 
there is clear biological plausibility. Further caveats relate to 
the fact that not all trials contributed data to these analyses 
and that PaCO
2
 change scores were mostly not adjusted for 
baseline differences. Nevertheless, it does suggest that there 
should be further investigation of the association between 
hypercapnia and clinical outcomes, particularly with regard 
Figure 6 hypercapnia and clinical outcomes.
Notes: (A) Mortality (rr) and baseline PaCO2. (B) Mortality (rr) and change in PaCO2. (C) hospital admissions (MD) and baseline PaCO2. (D) hospital admissions (MD) 
and change in PaCO2.
Abbreviations: rr, relative risk; PaCO2, partial pressure of carbon dioxide; MD, mean difference.
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to the ability of the NIV to reduce PaCO
2
 levels. Patients 
hypercapnic at discharge may normalize their PaCO
2
 
levels over time, although those who remain hypercapnic 
have higher mortality.47 Thus, if hypercapnia (or change in 
hypercapnia) were a driver of NIV response and were used 
to select patients for treatment after an exacerbation, subse-
quent reassessment may be needed to determine likelihood 
of ongoing benefit.
The current recommendation in the UK suggests that 
domiciliary NIV is considered on health economic grounds 
if a patient has had three hospital admissions with acute 
hypercapnic respiratory failure.48 There may be other, as 
yet unconfirmed, patient characteristics which influence its 
effectiveness. Uncertainty also remains regarding the length 
of time NIV may provide benefit for; there are at least two 
RCTs49,50 looking at the effect of discontinuing NIV, but this 
question was beyond the scope of this systematic review.
strengths and limitations
A number of RCTs of reasonably good methodological 
quality were available, particularly for the stable population, 
and a comprehensive search strategy meant that this system-
atic review identified more relevant studies than previous 
ones, even after taking into account different search periods. 
No language restrictions meant that 19% of the included stud-
ies were non-English, a substantial proportion of the overall 
evidence base omitted by prior reviews.8–11 This is also the 
first systematic review to examine patient-related outcomes 
and incorporate data from nonrandomized studies. Further-
more, by calculating summary measures from raw data or 
converting data, the number of results that could be presented 
in forest plots was maximized. In contrast to some previous 
systematic reviews, secondary outcome data (lung function, 
blood gases, and 6-minute walk distance) were not pooled 
due to a lack of results adjusted for baseline differences. This 
means that our analyses are likely to be more robust.
There were several limitations in the available data, 
largely due to inconsistency of reporting (particularly for 
hospital admissions) or measurement tools (especially for 
QoL). This meant that not all available evidence could 
contribute to the pooled estimates. Furthermore, admis-
sions data may be skewed; thus, the mean (SD) may not 
be an appropriate metric to use, though it was frequently 
reported. For primary outcomes, there was a lack of data 
explicitly linking the number of exacerbations to subsequent 
hospitalizations and survival for individual patients. This 
latter point has potential implications for double-counting 
data as these outcomes are not independent of each other. 
Ventilator settings may influence effectiveness, and settings 
have changed over time, such that earlier settings may be 
considered ineffective today. The small crossover trials38–40 
in this analysis did not allow any conclusions to be drawn, 
and subgroup analysis based on the larger/parallel trials was 
not possible due to inconsistent reporting: studies variously 
reported mean, median, or target settings, based on pressure, 
blood gas, or volume targets, with some stating only that 
levels were adjusted to patient comfort/tolerance. Reporting 
times also varied (eg, at start of study or at discharge).
recommendations for future research 
pertaining to domiciliary nIV in COPD
Variable quality of data reporting, lack of exacerbation data, 
potential bias, and heterogeneity of reported outcomes were 
striking features of the included studies. These features are 
not uncommonly encountered when conducting systematic 
reviews. While trials of medications are often required to 
report certain outcomes as part of the licensing process, 
medical device studies, such as those included in our review, 
have not always had to meet such standards despite also 
being subject to regulatory processes. More detailed report-
ing of exacerbations in particular would be valuable in this 
high-risk population. It has been suggested that new RCTs 
could include a sham NIV arm in order to minimize potential 
bias, as well as high- and low-pressure NIV arm to enable 
further exploration of the relationship between pressure 
and effectiveness; many of the earlier studies included used 
pressures which experts would now consider equivalent 
to a sham treatment.19 However, sham NIV could lead to 
an overestimate of the potential benefit of NIV, due to its 
potential disbenefits on QoL; therefore, two control arms 
(with and without sham NIV) are more likely to be appro-
priate. Qualitative work in NIV users and prescribers not 
surprisingly suggests that a focus on patient-centered mea-
sures (eg, QoL, daily activity) is needed, alongside research 
to delineate those in whom the treatment is most effective.46 
Which instruments best capture QoL in this patient group and 
whether instruments are convertible is debatable.
There is at least one ongoing trial (the UK HOT-HMV 
trial, NCT00990132), which includes a population with 
an underlying risk of recurrent events similar to the post-
hospital population described in this study. Findings from 
this trial will be important, but additional evidence from 
individual patient data analyses of pooled studies may be 
required to determine whether specific patient characteris-
tics or equipment settings predict benefit from NIV, and to 
establish optimum time points for starting (and potentially 
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discontinuing) NIV. A previous review8,9 attempted such 
analyses, but based on a smaller group of studies, and without 
considering hospitalizations or survival.
Conclusion
The effectiveness of domiciliary NIV remains uncertain; 
however, some patients appear to benefit. Further research is 
required to identify these patients and to explore the relevance 
of hypercapnic status or changes in hypercapnia due to NIV 
in influencing clinical outcomes for patients on long-term 
NIV; optimum time points for starting NIV and equipment 
settings also need to be established.
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